# QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

> **NCT07560449** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 162 (estimated)

## Conditions studied

- Malignant Plasma Cell Neoplasms

## Interventions

- **DRUG:** QLS4131
- **DRUG:** QL2109
- **DRUG:** Pomalidomide
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07560449
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2030-06
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560449, "QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07560449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*